Levi & Korsinsky, LLP Investigates Possible Breach of Fiduciary Duty by the Board of HealthTronics, Inc. - HTRN

Levi & Korsinsky is investigating the Board of Directors of HealthTronics, Inc. (“HealthTronics” or the “Company”) (NasdaqGS: HTRN) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to sell the Company to Endo Pharmaceuticals Holdings Inc. ("Endo Pharmaceuticals") (NasdaqGS: ENDP). Under the terms of the transaction, HealthTronics shareholders will receive $4.85 in cash for each share of HealthTronics that they own for a total transaction value of approximately $223 million, including assumption of debt.

The investigation concerns whether the HealthTronics Board of Directors breached their fiduciary duties to HealthTronics stockholders by failing to adequately shop the Company before entering into this transaction and whether Endo Pharmaceuticals is underpaying for HealthTronics shares, thus unlawfully harming HealthTronics stockholders. In particular, at least one analysts set a price target for HealthTronics stock at $7.00 per share.

If you own common stock in HealthTronics and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at [e-mail] or by telephone at [phone] or visit http://www.zlk.com/healthtronics-htrn.html.

Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation.